Udumyan R, Montgomery S, Fang F, et al. - Using prospectively gathered data from Swedish population and health registers, researchers determined the link between β-blocker use at the time of cancer diagnosis and lung cancer mortality in this retrospectively defined nationwide cohort study including the largest general population-based cohort of patients with non-small cell lung cancer (NSCLC) to date. They selected 18,429 patients who received a diagnosis of a primary NSCLC between 2006 and 2014 and were observed up to 2015. The deaths of 14,994 patients (including 13,398 from lung cancer) were reported during the median follow-up of 10.2 months. Findings revealed no link between beta-blocker use and lung cancer mortality when evaluated in aggregate in the total cohort, but proof for some beta-blockers is less conclusive. Overall, it is not indicated by the findings that cancer-specific mortality rate in NSCLC patients is reduced as a result of beta-blocker use at lung cancer diagnosis.